UPDATE: Stifel Nicolaus Initiates ImunoGen at Hold; Reinvestment Limits EPS Growth

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Stifel Nicolaus initiated its coverage on ImunoGen (NASDAQ: IMGN) with a Hold rating. Stifel Nicolaus said, "Given the relatively short lifespan of the T-DM1 royalty stream (compared to the branded life span of most biologic therapies, such as Epogen, Rituxan, and Herceptin itself, which can run 15-20 years), we expect ImmunoGen to re-invest the royalties as opposed to driving EPS growth. As a result, we believe there is little upside potential for the shares from current levels, even if T-DM1 sales exceed expectations."ImmunoGen closed at $13.92 on Thursday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!